Plain-English translation of NCT06905405 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
This trial is testing whether advanced heart imaging can help doctors diagnose a condition called heart failure with preserved ejection fraction — where the heart doesn't pump blood out as forcefully as it should, even though it looks normal on standard tests. Half of the participants will also receive SGLT2 inhibitor therapy, a medication commonly used to treat heart and kidney conditions, to see if it helps improve their symptoms and exercise ability.
Many patients have symptoms of heart failure but don't meet the standard diagnostic criteria, making it hard for doctors to confirm the diagnosis and start treatment. This trial aims to develop better diagnostic tools using advanced imaging and to explore whether this medication could help patients who have unclear or borderline heart failure.
You likely qualify if…
You likely don't qualify if…
You will visit the heart failure clinic where you'll complete questionnaires about your quality of life and symptoms, and perform a six-minute walk test twice to measure your exercise capacity. You'll also undergo a heart MRI scan and a standard heart ultrasound (some images you may have already had will be reviewed). If you're in the treatment group, you'll take the heart medication daily; if you're in the observation group, you'll receive imaging and assessment only. The study involves detailed assessments using both standard and advanced imaging to improve diagnosis.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United Kingdom